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Abstract
Ultra-low-dose opioid antagonists enhance opioid analgesia and reduce analgesic tolerance and dependence by preventing
a G protein coupling switch (Gi/o to Gs) by the mu opioid receptor (MOR), although the binding site of such ultra-low-dose
opioid antagonists was previously unknown. Here we show that with approximately 200-fold higher affinity than for the mu
opioid receptor, naloxone binds a pentapeptide segment of the scaffolding protein filamin A, known to interact with the
mu opioid receptor, to disrupt its chronic opioid-induced Gs coupling. Naloxone binding to filamin A is demonstrated by
the absence of [3H]-and FITC-naloxone binding in the melanoma M2 cell line that does not contain filamin or MOR,
contrasting with strong [3H]naloxone binding to its filamin A-transfected subclone A7 or to immunopurified filamin A.
Naloxone binding to A7 cells was displaced by naltrexone but not by morphine, indicating a target distinct from opioid
receptors and perhaps unique to naloxone and its analogs. The intracellular location of this binding site was confirmed by
FITC-NLX binding in intact A7 cells. Overlapping peptide fragments from c-terminal filamin A revealed filamin A2561-2565 as
the binding site, and an alanine scan of this pentapeptide revealed an essential mid-point lysine. Finally, in organotypic
striatal slice cultures, peptide fragments containing filamin A2561-2565 abolished the prevention by 10 pM naloxone of both
the chronic morphine-induced mu opioid receptor–Gs coupling and the downstream cAMP excitatory signal. These results
establish filamin A as the target for ultra-low-dose opioid antagonists previously shown to enhance opioid analgesia and to
prevent opioid tolerance and dependence.
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Introduction
Ultra-low-dose opioid antagonists have been shown to enhance
opioid analgesia and attenuate tolerance and dependence, with a
mechanism long hypothesized as a blockade of excitatory signaling
opioid receptors [1–4]. Ultra-low-dose opioid antagonists can also
reverse hyperalgesia caused by acute, low-dose opioids to produce
analgesia [5]. Additionally, ultra-low-dose naltrexone has recently
been shown to attenuate opioid reward or addictive properties in
conditioned place preference [6] and self-administration and
reinstatement paradigms [7]. In a recent clarification of the
mechanism of action of ultra-low-dose opioid antagonists, we
showed that co-treatment with 10 ng/kg naloxone (NLX)
prevented a chronic morphine-induced, Gi/o-to-Gs switch in G
protein coupling by the mu opioid receptor (MOR) as well as a
coincident interaction of the Gbc dimer with adenylyl cyclase II
and IV [4]. While opioid receptors preferentially bind Gi and Go
proteins to inhibit adenylyl cyclase [8], chronic morphine induces
MOR–Gs coupling [4,9]. Although Chakrabarti et al (2005) also
demonstrated some MOR–Gs coupling in the opioid naı¨ve state
while we did not, we believe this difference may be due to their use
of non-immobilized anti-Ga antibodies producing some back-
ground binding by Fc receptors. First postulated as the sole
mediator of excitatory effects of opiates [10], the Gbc interacting
with adenylyl cyclases originates from the Gs protein coupling to
MOR and not from MOR’s native G proteins [11].
Ultra-low-dose opioid antagonists were initially thought to
preferentially bind a subset of MORs [1], and a Gs-coupling
MOR subpopulation was again recently proposed [9]. While it is
difficult to estimate the relative proportion of MORs signaling via
Gs versus Gi/o during tolerance, it seemed unlikely that the ultra-
low doses of NLX or naltrexone influencing opioid agonist effects
would be sufficient to selectively antagonize such a subpopulation.
Based on saturation binding studies [12], which incorporate
NLX’s affinity to MOR, we estimate receptor occupancy of
10 ng/kg NLX as no more than 1%. More importantly, our co-
immunoprecipitation data showed that ultra-low-dose NLX co-
treatment reduces MOR–Gs coupling while restoring levels of
coupling to MOR’s native Gi/o proteins; further, in spinal cord of
co-treated rats, MOR–Gi/o coupling levels greatly surpassed
those of opioid-naı¨ve rats [4]. If NLX were selectively antagoniz-
ing a subpopulation of ‘‘Gs-coupled’’ MORs, coupling to native G
proteins would likely be unaffected.
Since NLX prevents MOR–Gs coupling at concentrations well
below its affinity for MOR and by influencing the coupling
behavior of MORs, we considered proteins that interact with
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MOR and MOR-associated G proteins as the most likely targets,
particularly those able to interact with multiple MORs. We first
examined proteins that co-immunoprecipitated with MOR during
activation. We identified a 300-kDa protein co-immunoprecipi-
tating with MOR as FLNA and then demonstrated specific, high-
affinity binding by NLX to FLNA. Best known for cross-linking
cytoplasmic actin into dynamic scaffolds to control cell motility,
filamins are large cytoplasmic proteins increasingly found to
regulate cell signaling by interacting with over 30 different
receptors and signaling molecules [13,14], including MOR [15].
We deduced the precise binding site on FLNA by using
overlapping peptides within the c-terminal, since c-terminal FLNA
was shown to interact with MOR using a yeast-two hybrid [15].
To assess the functional significance of this high-affinity interac-
tion, we used peptide fragments containing the binding site to
prevent NLX from binding full-length FLNA in organotypic
striatal slice cultures. Our findings suggest that FLNA interacts
with ultra-low-dose NLX and naltrexone to prevent chronic
morphine-induced MOR–Gs coupling, possibly by preventing a
critical MOR–FLNA interaction. This high-affinity binding site in
c-terminal FLNA therefore appears to underlie the paradoxical
enhancement of opioid analgesia and prevention of analgesic
tolerance and dependence by ultra-low-dose opioid antagonists. In
identifying the binding site though which ultra-low-dose opioid
antagonists prevent MOR–Gs coupling, our data also reveal an
important regulation of MOR–G protein coupling by filamin A.
Results
Identification of NLX-binding protein in MOR
immunoprecipitates
In previous co-immunoprecipitation experiments of MOR and
G proteins, we noted a protein with molecular weight at
approximately 300-KDa in Gai/o immunoprecipitates in an
amount that closely paralleled the amount of MORs in these
immunoprecipitates, suggesting a functional interaction. A battery
of antibodies against various cytoskeletal proteins, preliminarily
identified this protein that co-immunoprecipitated with MORs
and their associated G proteins as FLNA. Using striatal tissue of
rats treated chronically with vehicle, morphine, ultra-low-dose
NLX or morphine+ultra-low-dose NLX, we performed a two-
tiered co-immunoprecipitation with anti-Ga followed by anti-
MOR antibodies. The final probing with a specific anti-FLNA
antibody showed that FLNA associates with Go-coupled MOR
and not with Gs-coupled MOR (Fig. 1 A,B). These blots also
demonstrate the morphine-induced G protein coupling switch by
MOR and its attenuation by co-treatment with ultra-low-dose
NLX. The blots were stripped and re-probed with antibodies to
MAP1B and yaotio to illustrate the absence of these cytoskeletal
proteins in these immunoprecipitates (Fig. 1C). The exclusive
presence of FLNA in the MOR/Go complexes led us to
hypothesize that FLNA is the target through which ultra-low-dose
NLX blocks the chronic morphine-induced switch from normal
MOR–Gi/o coupling to Gs coupling.
Figure 1. FLNA associates with Go-coupled MORs and not Gs-coupled MORs. Neuronal membranes were prepared from striata of rats
chronically treated with vehicle, morphine, or ultra-low-dose NLX alone or combined with morphine. After stimulation by in vitro morphine or not,
membranes were solubilized and immunoprecipitated first with immobilized anti-Ga. Anti-Ga immunoprecipitates were then immunoprecipitated
with immobilized anti-MOR before final Western blot detection with anti-FLNA. Densitometric quantitation (B) of Western blots of both MOR in the
second immunoprecipitate and FLNA in the final (A) demonstrates that FLNA is associated with MORs coupling to Go but not MORs coupling to Gs.
These blots and their quantitation also show that NLX co-treatment prevented the chronic morphine-induced Go-to-Gs coupling switch. Solid bars
indicate basal coupling, and hatched bars indicate coupling after receptor stimulation by in vitro morphine. n= 4. *p,0.05, **p,0.01 compared to
respective basal coupling level.# p,0.01 compared to respective value in vehicle or morphine+NLX groups. Blots were stripped and re-probed with
antibodies to yaotio, MAP2, H-neurofilament and MAP1B (C).
doi:10.1371/journal.pone.0001554.g001
pM Naloxone Binds Filamin A
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NLX binding in FLNA-expressing cells and affinity
measurement
To validate the binding of NLX to FLNA, we assessed binding
of [3H]NLX to membranes prepared from the human melanoma
cell line M2 that lacks filamin and to membranes from its FLNA-
transfected subclone A7. We first confirmed FLNA expression in
A7 cells and absence in M2 cells by Western blotting using a
specific anti-FLNA antibody (Table 1). FLNA was also detected in
the human neuroblastoma SK-N-MC cell line and in rat cortical
membranes (Table 1). Importantly, [3H]NLX bound to A7
membranes and this binding was robustly displaced by naltrexone
but not by morphine, illustrating that NLX and naltrexone bind to
a novel site distinct from MOR (Fig 2A). Negligible [3H]DAMGO
binding to A7 cells suggested that these cells (and presumably their
M2 parent line) do not express MORs (Fig. 2B). Finally, the
filamin-deficient M2 cells do not express molecules that bind
[3H]NLX (Fig. 2C).
In an affinity assessment, a competition (displacement) curve for
the inhibition of [3H]NLX binding to A7 cell membranes was
performed using 16 concentrations of naltrexone. Analysis by
nonlinear regression showed two saturable sites (R2 = 0.9788) with
an IC50-H of 3.94 picomolar and an IC50-L of 834 picomolar
(Fig. 3).
Precise NLX binding site determined using overlapping
peptides
To deduce the precise binding domain within FLNA where
NLX binds, several overlapping peptide sequences derived from
the carboxy-terminus where FLNA intersects with synaptic
membranes were used to absorb [3H]NLX. Both FLNA2556–2565
and FLNA2561–2570 markedly attenuated [
3H]NLX binding to A7
cell membranes and to purified human FLNA (Fig. 4). This result
was confirmed using FLNA purified from FLNA- and MOR-
expressing SK-N-MC cells. At 500 pM concentration, [3H]NLX
binds to immunoaffinity-purified FLNA in the presence or absence
of irreversible MOR antagonist, b-FNA. These data together
suggest that NLX binds with high affinity to FLNA with the
binding site located at FLNA2561–2565.
Figure 2. NLX target is distinct from MOR but also bound by
naltrexone. A, Naltrexone but not morphine markedly reduced
[3H]NLX binding in FLNA-expressing A7 membranes. n=6. B, The
absence of [3H]DAMGO binding using twice the amount of A7
membranes shows these lines do not express MOR. n=4. C, Parent
M2 melanoma cells do not express NLX targets. n= 4. * p,0.05
compared to control.
doi:10.1371/journal.pone.0001554.g002
Table 1. FLNA expression (Optical intensity of Western blot
bands, arbitrary units)
A7 cells M2 cells SK-N-MC cells Rat cortex
15 mg 825.8669.6 060 351.3663.9 230.3629.4
30 mg 2454.86259.9 060 983.8689.0 664.8667
Solubilized proteins (15 or 30 mg) from membrane preparations were size-
fractioned by 7.5% SDS-PAGE and electrophorectically transferred onto
nitrocellulose for Western blotting using specific anti-FLNA antibodies. n = 4.
doi:10.1371/journal.pone.0001554.t001
Figure 3. NLX binds A7 membranes with picomolar affinity. A
competition (displacement) curve for the inhibition of [3H]NLX binding
by naltrexone to membranes from FLNA-expressing A7 cells shows two
affinity states with IC50-H of 3.94 picomolar and IC50-L of 834 picomolar.
A nonlinear curve-fit analysis was performed using a competition
equation that assumed two saturable sites for the naltrexone curve
comprising of 16 concentrations ranging from 0.1 pM to 1 mM. Data are
derived from 6 experiments each using a different set of A7 cells.
doi:10.1371/journal.pone.0001554.g003
pM Naloxone Binds Filamin A
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Confirmation of pentapeptide binding and alanine scan
To confirm that FLNA2561–2565 binds NLX and to deduce
the critical amino acid(s) within the NLX interacting
FLNA2561–2565 region, we generated 4 alterations of
FLNA2561–2565 each with 1 amino acid replaced by alanine
(alanine scan). Using FLNA2561–2565 and the alanine-replaced
pentapeptides to compete with [3H]NLX binding to FLNA in A7
cell membranes, we show that the lysine residue at FLNA2663 is
critical to the NLX–FLNA interaction. While the FLNA2561–2565
displacement of [3H]NLX binding was only slightly attenuated by
alanine substitutions at the first, fourth and fifth amino acid
residues, substitution of the lysine completely prevented it (Fig. 5).
The notion that NLX binds to the extreme carboxyl terminus of
FLNA that tethers to the internal potion of cell membranes is
supported by our data illustrating that FLNA2561–2565 (VAKGL)
prevented the [3H]- and FITC-NLX labeling that localized
internally in intact A7 but not M2 cells (Fig. 6). This labeling
occurred without membrane permeabilization, indicating that
NLX can easily penetrate cell membranes to access FLNA.
Peptide binding site interferes with NLX’s prevention of
MOR–Gs coupling induced by chronic morphine
To confirm that NLX binding to FLNA prevents the chronic
morphine-induced Gi/o-to-Gs coupling switch, we utilized
organotypic rat brain striatal slice cultures. We previously showed
that in vivo chronic morphine induced a switch to MOR–Gs
coupling in rat striatum, periaqueductal gray and dorsal spinal
cord from Gi or Go coupling in these latter two regions but from
an exclusive Go coupling in striatum [4]. To mimic the in vivo
chronic morphine treatment and resulting opioid tolerance in that
study, rat striatal slices were treated for 7 days twice daily for 1 hr
with 100 mM morphine in serum-free culture medium. This
morphine treatment induced a robust Go-to-Gs coupling switch,
similar to that previously observed following in vivo chronic
morphine, that was also similarly blocked by co-treatment with
ultra-low-dose (10 pM) NLX (Fig. 7). The addition of
FLNA2561–2570 but not FLNA2550–2560 or FLNA2566–2575 abolished
NLX’s prevention of the Go-to-Gs coupling switch, presumably by
preventing NLX from binding FLNA in the tissue (Fig. 7).
Densitometric quantitations of blots from slices treated with NLX
or FLNA peptides alone did not differ from those of vehicle and
are omitted from Fig. 7B for simplification.
Consistent with the G protein coupling switch, morphine
treatment also increased basal cAMP levels, caused DAMGO to
stimulate cAMP production, and attenuated the DAMGO-
mediated reduction in forskolin-stimulated cAMP accumulation
(Fig. 8). As with the coupling switch, the addition of FLNA2561–2570
but not FLNA2550–2560 or FLNA2566–2575 abolished NLX’s
prevention of these cAMP indices of morphine tolerance.
Treatment with NLX or FLNA peptides alone did not alter
cAMP levels from those of vehicle (data not shown). These data
together suggest that ultra-low-dose NLX prevents analgesic
tolerance in response to chronic morphine by binding to a specific
region of FLNA.
Figure 4. FLNA2561–2565 is the binding site for [
3H]NLX. A7 cell
membranes or purified FLNA was incubated with [3H]NLX in the
presence of various overlapping FLNA c-terminal peptide fragments.
Peptides containing FLNA2561–2565 markedly reduced [
3H]NLX binding
to A7 membranes (A) and to purified FLNA (B, C). The reduction of
[3H]NLX binding to purified FLNA was not affected by the presence of
the irreversible MOR antagonist b-FNA (C). n= 6. * p,0.01 compared to
vehicle.
doi:10.1371/journal.pone.0001554.g004
Figure 5. Mid-point lysine of FLNA2561–2565 is critical for NLX
binding. An alanine scan of the FLNA2561–2565 pentapeptide (VAKGL)
shows that residue of FLNA2561–2565 is critical for NLX binding. All other
individual alanine substitutions only mildly attenuated [3H]NLX binding
to FLNA in A7 membranes. n=6. * p,0.01 compared to vehicle.
doi:10.1371/journal.pone.0001554.g005
pM Naloxone Binds Filamin A
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Discussion
We have identified a high-affinity binding site for NLX in the
carboxyl-terminal region of the scaffolding protein FLNA that
appears to mediate ultra-low-dose NLX’s prevention of the chronic
opioid-induced G protein coupling switch by MOR. This finding
further elucidates the mechanism of action of certain ultra-low-dose
opioid antagonists in enhancing opioid analgesia and preventing
opioid tolerance and dependence [4]. We measure the binding
affinity of NLX or naltrexone to FLNA in cell membranes as 4
picomolar, i.e. approximately 200-fold higher than their binding
affinity for MOR [16,17]. To our knowledge, this is the first
demonstration of picomolar binding by a psychoactive compound
that is not to a cell surface receptor. NLX binds FLNA tightly with
critical involvement of a 5-amino acid segment that is intracellular
but near its c-terminal transmembrane domain.
The presence of FLNA in MOR signalplex in native brain
tissues demonstrated here by co-immunoprecipitation agrees with
previous data using yeast-two hybrid and co-transfection methods
[15]. The dependence of [3H]NLX binding on FLNA expression
in cell lines, the absence of MOR in these cell lines, and the
displacement by naltrexone but not morphine clarified FLNA as a
novel target for NLX and naltrexone. The interaction was
confirmed using immunopurified FLNA from A7 or SK-N-MC
cells. Since FLNA2556–2565 and FLNA2561–2570 both markedly
reduced [3H]NLX binding to A7 membranes or to purified FLNA
proteins, we assumed that FLNA2561–2565, within the 24
th repeat,
is the NLX-binding site on FLNA. We confirmed FLNA2561–2565
as the binding site by showing NLX binding to this pentapeptide,
and an alanine scan revealed that the lysine at FLNA2563 is critical
for binding. We cannot easily explain a modest enhancement in
NLX binding caused by FLNA2575–2583, but this could be the
result of reducing steric constraints around the NLX binding site on
FLNA. Our demonstration that FLNA2561–2565 (VAKGL) but not
VAAGL abolished [3H]- and FITC-NLX binding to intact A7 cells
again confirmed that this pentapeptide is a NLX binding site and
demonstrated that NLX can access this intracellular target. Finally,
the blockade of NLX’s protective effects on both Gs coupling and
cAMP accumulation by peptides containing FLNA2561–2565 provides
evidence that ultra-low-dose NLX may block MOR–Gs coupling
and associated opioid tolerance and dependence by binding to
FLNA at approximately FLNA2561–2565. Although MOR desensiti-
zation, i.e. the decrease in coupling to native G proteins, is more
commonly thought to underlie opioid tolerance and dependence
[18,19] than a switch to Gs coupling, our present data indicate that a
decrease in MOR efficacy can not alone mediate chronic opioid
effects. Specifically, the increase in cAMP accumulation caused by
DAMGO without forskolin following chronic morphine treatment
illustrates that MOR has not merely desensitized, losing its ability to
inhibit cAMP production, but that its stimulation actually augments
cAMP production.
The detection of FLNA in immunoprecipitates containing Go-
coupled MOR and not Gs-coupled MOR appears counterintuitive
since NLX prevents MOR–Gs coupling via a tight binding to
FLNA. We propose that repeated MOR stimulation may force a
particular conformation of the MOR-FLNA complex that
weakens the entire signalplex. MOR may subsequently release
from both its native G protein and from FLNA itself leading to
association with Gs without FLNA in the complex. By binding to
FLNA, NLX could block this particular MOR–FLNA interaction
and stabilize the MOR-FLNA-G protein complexes, thereby
reducing the morphine-induced release of MORs and their
subsequent coupling with Gs in response to receptor stimulation.
MOR and FLNA might be forced into an altered conformation or
interaction during opioid tolerance by proteins involved in MOR
recycling and internalization such as b-arrestins [20]. Additionally,
as exogenous GM1 ganglioside has been shown to mimick opioid
tolerance in vitro [21] and since blocking GM1 ganglioside via
cholera toxin B subunit also blocks the excitatory effects of opiates
in vitro [22] and in vivo [23], GM1 ganglioside may also influence
MOR–FLNA interactions. Interestingly, although we observed
FLNA in MOR signalplexes containing Go proteins in native
brain tissue, the prior data in co-transfected cells indicates that
FLNA is not required for the native coupling state of MOR; in
fact, its absence actually enhances MOR function [15].
This prior study by Onoprishvili et al., the first to show that
FLNA interacts with the c-terminal of MOR, proposed a role for
FLNA in receptor regulation and trafficking [15]. The authors
reported that MOR functioned normally in cells lacking FLNA,
but that the agonist DAMGO was unable to desensitize MOR, as
measured by the decreased ability of DAMGO to inhibit forskolin-
mediated cAMP accumulation following prolonged DAMGO
exposure. In agreement, our present slice culture data show that
ultra-low-dose NLX, by binding to FLNA, prevents this morphine-
induced desensitization measure, as well as the upstream MOR–
Gs coupling that we previously showed to underlie tolerance and
Figure 6. [3H]- and FITC-NLX binding to intact A7 cells is
blocked by FLNA2561-2565. Intact A7 and M2 cells were incubated
with 0.5 nM [3H]NLX or 10 nM FITC-NLX in the presence or absence of
10 nM VAKGL or VAAGL. [3H]NLX bound to A7 but not to M2 cells and
VAKGL markedly reduced this binding to A7 cells (A). Likewise, FITC-NLX
labelled A7 (B.I) but not M2 cells (B.II), and co-treatment with VAKGL
(B.III) but not VAAGL (B.IV) abolished this FITC-NLX labelling in A7 cells
(B). n= 4. * p,0.01 compared to vehicle.
doi:10.1371/journal.pone.0001554.g006
pM Naloxone Binds Filamin A
PLoS ONE | www.plosone.org 5 February 2008 | Volume 3 | Issue 2 | e1554
Figure 7. FLNA2561-2565 blocks 10 pM NLX’s prevention of the chronic morphine-induced Go-to-Gs coupling switch. Striatal slices were
chronically treated with vehicle, morphine, NLX, morphine+NLX, or with one of the three FLNA peptides alone or in combination with morphine+NLX.
Coupling between MOR and Gs/Go proteins was assessed by Western blot (A) and analyzed by densitometric scanning (B). Chronic morphine
exposure caused a Go-to-Gs coupling switch that was blocked by NLX co-treatment. NLX’s suppression of this coupling switch was blocked by
FLNA2561-2570 but not by FLNA2566–2575 or FLNA2550–2560, illustrating that NLX’s protective effect occurs via its binding to FLNA within FLNA2561–2570.
Solid bars indicate basal coupling; hatched bars indicate coupling after in vitro morphine stimulation. n= 6. *p,0.01 compared to Kreb’s Ringer;
+p,0.01 compared to morphine; #p,0.01 compared to morphine+NLX.
doi:10.1371/journal.pone.0001554.g007
pM Naloxone Binds Filamin A
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dependence in vivo [4]. Rather than desensitization, Onoprishvili et
al. actually noted enhanced inhibition by DAMGO of cAMP
accumulation in cells lacking FLNA [15], a finding that also agrees
with the idea that in signaling complexes that do not contain
FLNA, MOR does not release from its Gi/o protein to interact
with Gs. This increased Gi/o recruitment leading to heightened
DAMGO-induced cAMP inhibition also concurs nicely with the
increased Gi/o coupling we previously observed in spinal cord of
animals treated with morphine+ultra-low-dose NLX [4], as well as
with the enhanced analgesia that follows these co-treatments [2].
It is possible that the ultra-low-dose opioid antagonist
attenuation of opioid addictive properties [6,7] may also be
mediated by this high-affinity binding to FLNA. While the
enhancement of opioid analgesia and reduction of analgesic
tolerance is ‘‘paradoxical,’’ and occurs only at ‘‘ultra-low’’ doses of
NLX and naltrexone (since higher doses of these opioid
antagonists also antagonize opioid receptors), the attenuation of
rewarding or addictive properties of opioids by ultra-low-dose
naltrexone is not paradoxical. Hence, one would expect a
continuous suppression of reward as increasing doses of naltrexone
are combined with the opioid. Yet, in the conditioned place
preference paradigm, while both ultra-low (0.03 and 0.3 ng/kg)
and higher (30 ng/kg) naltrexone doses blocked the acute
rewarding effects of oxycodone, an interim dose (3 ng/kg) was
without effect [6]. Similarly, in a self-administration paradigm,
while co-self-administering 10 or 1 pg/kg/infusion both attenuat-
ed measures of reinstatement when oxycodone was not available,
only the lower dose altered oxycodone’s rewarding potency during
self-administration [7]. The blunting of opioid rewarding effects by
ultra-low-dose naltrexone first suggests that Gs coupling by MOR
may contribute to the rewarding or addictive properties of opioids,
possibly by cAMP activation of PKA and subsequent CREB
phosphorylation. However, opioid inhibitory effects, such as the
proposed disinhibition of VTA dopamine neurons via inhibition of
GABA interneurons [24], may also contribute to opioid reward.
The loss of effect at intermediate naltrexone doses may indicate
such complexities of the neural mechanisms contributing to opioid
reward and addiction. Alternatively, the fact that the attenuation
of rewarding effects is diminished as the naltrexone dose increases
could also suggest an upper limit of an effective ultra-low dose
range for disrupting the FLNA–MOR interaction and consequent
MOR–Gs signaling.
In summary, here we identify a specific c-terminal region of
FLNA as the high-affinity binding site of NLX and naltrexone in
their suppression of MOR signaling alterations that result from
chronic opioid treatment. This work therefore provides a
molecular target for ultra-low-dose NLX through which ultra-
low-dose opioid antagonists enhance opioid analgesia and
decrease opioid tolerance and dependence. We propose that
repeated MOR stimulation leads to a particular conformation of
MOR–FLNA that weakens Gi/o–MOR–FLNA complexes and
allows MORs to release to interact with Gs upon subsequent
stimulation by morphine. By binding to FLNA, NLX and its
analogs prevent this altered MOR–FLNA interaction, thereby
preventing the release from the complexes and the resultant altered
coupling. There are multiple signaling consequences of the switch to
Gs coupling by MORs chronically exposed to opioids, and each may
contribute differently to the various behavioral effects of long-term
opioid administration such as analgesic tolerance, physical depen-
dence and the possibility of addiction. This notion may explain the
multiple beneficial effects of ultra-low-dose opioid antagonist co-
treatment, shown to preserve the normal G protein coupling profile
of MOR [4]. By identifying the target and binding site of ultra-low-
dose NLX and naltrexone, we further elucidate their mechanism of
action when combined with opioids. Finally, these findings create an
opportunity to formulate a new generation of pain therapeutics that
may provide long-lasting analgesia with minimal tolerance,
dependence and addictive properties.
Methods
Animals
Male Sprague Dawley rats (200-250 g) purchased from Taconic
(Germantown, NY) were housed two per cage and maintained on
a regular 12-hr light/dark cycle in a climate-controlled room with
food and water available ad libitum. For identification of NLX-
binding protein in MOR immunoprecipitates, four groups of 4
Figure 8. FLNA2561–2565 blocks 10 pM NLX’s prevention of chronic morphine-induced cAMP accumulation. After chronic treatments,
slices were stimulated with DAMGO, forskolin or DAMGO+forskolin before solubilizing tissues and measuring cAMP levels. In accordance with the Go-
to-Gs coupling switch, chronic morphine increased basal cAMP production by 24%, caused DAMGO to stimulate basal cAMP production, and reduced
the DAMGO-mediated inhibition of the forskolin effect from 35% in vehicle/NLX groups to 7%. NLX co-treatment blocked these morphine-induced
effects, and the protective effect of NLX was blocked by FLNA2561–2570 but not by FLNA2566–2575 or FLNA2550–2560, again demonstrating that NLX’s
protection occurs through binding to FLNA within FLNA2561–2570. n= 4. *p,0.01 compared to forskolin alone. +p,0.01 compared to vehicle.
##p,0.05, #p,0.01 compared to basal level.
doi:10.1371/journal.pone.0001554.g008
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rats were treated twice daily for 7 days with vehicle, NLX
(10 ng/kg, s.c.), morphine (10 mg/kg, s.c.), or morphine+NLX.
These animals were sacrificed by decapitation 16 hr after the
last injection, and whole striatum was harvested on ice
immediately. For organotypic striatal slice cultures, brain slices
harvested from treatment-naı¨ve rats were maintained and treated in
vitro as described below. All procedures in this protocol are in
compliance with the City College of New York IACUC on the use
and care of animals.
Identification of FLNA in MOR immunoprecipitates
Neuronal membranes (200 mg) were prepared as described
previously [4,25] from striata of rats treated as described above.
Membranes were incubated with 1 mM morphine for 5 min at
37uC in Kreb’s Ringer solution before solubilization in immuno-
precipitation buffer (25 mM HEPES, pH 7.5; 200 mM NaCl,
2 mM MgCl2, 1 mM EDTA, 0.2% 2-mercaptoethanol, 50 mg/ml
leupeptin, 25 mg/ml pepstatin A, 0.01 U/ml soybean trypsin
inhibitor, 0.04 mM phenylmethylsulfonyl floride [PMSF]) con-
taining 0.5% digitonin, 0.2% sodium cholate and 0.5% NP-40 at
4uC with end-over-end shaking for 60 min. The supernatant was
collected after centrifugation at 50,000 X g for 5 min to remove
insoluble debris before immunoprecipitation. MOR and its
associated scaffolding proteins and G proteins were immunopur-
ified together using anti-Gas/olf or -Gao antibodies that were
immobilized to prevent interference from immunoglobulins. Anti-
Ga antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were
covalently cross-linked to protein A conjugated resin in a Seize-X
protein A immunoprecipitation kit (Pierce-ENDOGEN, Rockford,
IL) according to manufacturer’s instructions. MOR-G protein-
scaffolding protein complexes in solubilized brain lysate were first
isolated by immunoprecipitation in which 200 mg solubilized brain
membrane extract from striatum was incubated with immobilized
anti-Ga-protein A-resin at 4uC overnight. After centrifugation and
three washes with phosphate-free Kreb’s-Ringer (pH 7.4) con-
taining mixtures of protease and protein phosphatase inhibitors at
4uC, the MOR-G protein-scaffolding protein complexes were
eluted with 200 ml of neutral pH gentle antigen elution buffer,
diluted 5-fold with immunoprecipitation buffer, and immunopre-
cipitated with anti-MOR at 4uC for 4 hr followed by 50 ml protein
A/G-conjugated beads (Santa Cruz Biotechnology) for 2 hr. The
immunoprecipitates containing MOR-G protein-scaffolding pro-
tein complexes were collected by centrifugation and washed twice
with phosphate-free Kreb’s-Ringer. The washed immunocomplex
was re-suspended in 75 ml phosphate-free Kreb’s-Ringer and
solubilized by combining with 75 ml of 2X PAGE sample
preparation buffer (62.5 mM Tris-HCl, pH6.8; 20% glycerol,
4% SDS; 10% 2-mercaptoethanol, 0.1% bromophenol blue) and
boiled for 5 min. The levels of selective MOR-associated
scaffolding proteins were determined by Western blotting using
specific antibodies directed against various cytoskeletal and
scaffolding proteins including FLNA, MAP1B and yaotio.
NLX binding to FLNA-expressing cells
To confirm FLNA as the high-affinity target of NLX, we
assessed [3H]NLX binding to the human melanoma cell line M2
subclone that was stably transfected with human filamin A cDNA
(obtained from Drs. Stossel and Ohta at Harvard Medical School).
Membranes prepared from A7 cells (100 mg) were incubated in
binding medium (50 mM Tris HCl, pH7.5; 100 mM NaCl; and
protease and protein phosphatase inhibitors) with 500 pM
[3H]NLX in the presence of 10 mM of either morphine or NTX
at 37uC for 30 min. Total incubation volumes were 500 ml. Non-
specific binding was defined by 1 mM NTX. Membranes prepared
from the parent M2 cells (200 mg) that do not express FLNA
served as a negative control for [3H]NLX binding, and A7 cell
membranes (200 mg) incubated with 2 nM [3H]DAMGO illus-
trated the lack of MOR in both cell lines. Reactions were
terminated by rapid filtration through 3% BSA-treated GF/B
membranes under vacuum. Filters were washed twice with 5 ml
ice-cold binding medium, and [3H]NLX retained on the filters was
measured by liquid scintillation spectrometry.
In a separate experimental series, whole cell binding of
[3H]NLX in intact A7 and M2 was performed. A7 and M2 cells
were grown on 35-mm dishes until 80% confluent. After two
washes with PBS (37uC), [3H]NLX (0.5 nM) was added to cells
and incubated for 30 min at 37uC in the absence or presence of
10 mM pentapeptide FLNA fragment, VAKGL. Following
removal of [3H]NLX containing binding medium, cells were
washed twice with PBS (37uC), collected and [3H]NLX in cells
were counted by scintillation spectrometry.
To visualize NLX binding, A7 and M2 cells were grown on
chambered slides (Nalge Nunc, Naperville, IL) to 80% confluency.
FITC-NLX (10 nM, Invitrogen) was added to the cells in 0.5%
FBS-containing culture medium and incubated for 30 min at
37uC in the presence or absence of 10 mM VAKGL or VAAKGL.
Following incubation, medium was removed and cells were
washed three times with warm PBS. Cells were then fixed in
10% formalin-PBS overnight at 4uC and coverslipped. The bound
FITC-NLX was visualized with a fluorescence microscope.
Affinity measurement
A competition (displacement) curve was generated for the
inhibition of [3H]NLX binding by naltrexone to membranes
prepared as described above from FLNA-expressing A7 cells. A
nonlinear curve-fit analysis was performed using competition
equation that assumed two saturable sites for naltrexone curve
comprising of 16 concentrations ranging from 0.1 pM to 1 mM.
Six experiments each using a different set of A7 cells were included
in the analysis.
Determination of binding site using FLNA peptides
To determine the NLX binding site on FLNA, various
overlapping peptides encoding the c-terminal section of FLNA
were used to compete for [3H]NLX binding to FLNA using either
A7 cell membranes or purified FLNA from A7 or SK-N-MC cells.
Peptides were generated by Sigma-Genosys (The Woodlands,
TX). The reaction mixture consisted of 100 mg A7 membranes or
2 mg purified FLNA, 500 pM [3H]NLX, and 10 mM of either
FLNA2550–2560, FLNA2556–2565, FLNA2561–2570, FLNA2566–2575 or
FLNA2576–2581 in 500 ml binding medium. With FLNA purified
from SK-N-MC cells, 1 mM of the irreversible MOR antagonist b-
funaltrexamine (b-FNA) was used to demonstrate binding
independent of MOR. The reactions were carried out at 37uC
for 30 min and terminated by rapid filtration through 3% BSA-
treated GF/B membranes under vacuum. Filters were washed
twice with 5 ml ice-cold binding medium, and [3H]NLX retained
on the filters was measured by liquid scintillation spectrometry.
Alanine scan of pentapeptide on FLNA binding
To determine the essential amino acid(s) within the NLX-
interacting pentapeptide, four additional pentapeptides, each with
one amino acid replaced by alanine, were used along with the
correct FLNA2561-2565 pentapeptide to compete for [
3H]NLX
binding to FLNA using A7 cell membranes. Peptides were
generated by Sigma-Genosys. The reaction mixture consisted of
500 pM [3H]NLX, 200 mg A7 membranes, and 10 mM penta-
peptide (AAKGL, VAKGL, VAAGL, VAKAL or VAKGA) in
pM Naloxone Binds Filamin A
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500 ml binding medium. Reactions were conducted at 37uC
for 30 min and terminated by rapid filtration through 3%
BSA-treated GF/B membranes under vacuum. Filters were
washed twice with 5 ml ice-cold binding medium, and [3H]NLX
retained on the filters was measured by liquid scintillation
spectrometry.
Organotypic striatal slice cultures
In this set of experiments, rat brain slice organotypic culture
methods were modified from those published previously [26,27].
Striatal slices (200 mM thickness) were prepared using a McIlwain
tissue chopper (Mickle Laboratory Engineering Co., Surrey, UK).
Slices were carefully transferred to sterile, porous culture inserts
(0.4 mm, Millicell-CM) using the rear end of a glass Pasteur
pipette. Each culture insert unit contained 2 slices and was placed
into one well of the 12-well culture tray. Each well contained
1.5 ml of culture medium composed of 50% MEM with Earl’s
salts, 2 mM L-glutamine, 25% Earl’s balanced salt solution, 6.5 g/
l D-glucose, 20% fetal bovine serum, 5% horse serum, 25 mM
HEPES buffer, 50 mg/ml streptomycin and 50 mg/ml penicillin.
The pH was adjusted to 7.2 with HEPES buffer. Cultures were
first incubated for 2 days to minimize the impact of injury from
slice preparation. Incubator settings throughout the experiment
were 36uC with 5% CO2.
To induce tolerance, culture medium was removed and the
culture insert containing the slices was gently rinsed twice with
warm (37uC) phosphate-buffered saline (pH 7.2) before incubation
in 0.1% fetal bovine serum-containing culture medium with
100 mM morphine for 1 hr twice daily (at 9–10 AM and 3–4 PM)
for 7 days. To assess the effect of ultra-low-dose of NLX on the
chronic morphine-induced signaling switch, some slices were
exposed to 100 mM morphine plus 10 pM NLX. To determine
whether NLX’s protective effect occurs by binding to FLNA at
FLNA2561–2565, slices were incubated with morphine plus NLX
with the addition of 10 mM FLNA2550–2560, FLNA2561–2570, or
FLNA2566–2575. Slices were returned to culture medium with
normal serum after each drug exposure. Tissues were harvested
16 hr after the last drug exposure by centrifugation.
MOR–Gs coupling in slice cultures
For determination of MOR–G protein coupling, slices were
homogenized to generate neuronal membranes. Membranes
(400 mg), prepared as described above, were incubated with either
1 mM morphine or Kreb’s-Ringer solution for 10 min before
solubilization in 250 ml of immunoprecipitation buffer (25 mM
HEPES, pH7.5; 200 mM NaCl, 1 mM EDTA, 50 mg/ml
leupeptin, 10 mg/ml aprotinin, 2 mg/ml soybean trypsin inhibitor,
0.04 mM PMSF and mixture of protein phosphatase inhibitors).
Following centrifugation, striatal membrane lysates were immu-
noprecipitated with immobilized anti-Gas/olf or -Gao conjugated
with immobilized protein G-agarose beads. The level of MOR in
anti-Gas/olf or -Gao immunoprecipitates was determined by
Western blotting using specific anti-MOR antibodies.
cAMP accumulation in slice cultures
To measure the magnitude of MOR-mediated inhibition of
cAMP production, brain slices were incubated with Kreb’s-Ringer
(basal), 1 mM DAMGO, 1 mM forskolin or 1 mM DAM-
GO+1 mM forskolin for 10 min at 37uC in the presence of
100 mM of the phosphodiesterase inhibitor IBMX. Tissues were
homogenized by sonication and protein precipitated with 1M
TCA. The supernatant obtained after centrifugation was neutral-
ized using 50 mM Tris, pH 9.0. The level of cAMP in the brain
lysate was measured by a cAMP assay kit (PerkinElmer Life
Science, Boston, MA) according to manufacturer’s instructions.
Data analysis
All data are presented as mean6standard error of the mean.
Treatment effects were evaluated by two-way ANOVA followed by
Newman-Keul’s test for multiple comparisons. A two-tailed Student’s
t test was used for post hoc pairwise comparisons. Data are presented as
means6s.e.m. The threshold for significance was p,0.05.
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